Share
The UK Column is an independent news organisation analysing the information war. Operating without financial backing or external investment, we remain free from advertisers, foundations, and political parties, relying solely on support from our audience through memberships and donations.
…
continue reading
Manage episode 519857164 series 3579126
Content provided by Gene Quinn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Gene Quinn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Every life-saving drug we know of—every cancer therapy, every vaccine, every breakthrough—started as an impossible idea. Turning that idea into reality takes more than science. It takes persistence, investment, and a patent system strong enough to protect innovation. In this episode of IPWatchdog Unleashed, Gene Quinn (IPWatchdog) sits down with Rob Sahr, a Shareholder at Wolf Greenfield, to unpack the extraordinary journey from molecule to medicine. Together, they explore how scientific breakthroughs depend not only on research and capital, but also on a stable and predictable patent system. From double patenting and government funding to judicial uncertainty and policy headwinds, the conversation dives into the fragile balance between innovation and access—and the miracles required to bring new drugs to life.
Visit us online at IPWatchdog.com.
You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.
77 episodes
))
